Back to today’s briefing

Story perspectives

Nuravax Secures $3M Grant for Alzheimer's Vaccine Trials

5/7/2025

48 10

Summary

Story summary

Nuravax Inc. has secured a $3 million grant from the NIH to propel its Alzheimer’s vaccine, Duvax, into human trials. This innovative vaccine aims to combat cognitive decline by targeting amyloid beta and tau proteins. Additionally, a promising new vaccine focusing on phosphorylated tau has demonstrated success in animal studies, reducing tau accumulation and enhancing memory, paving the way for affordable Alzheimer’s treatments.

1 of 1

Story summary

Nuravax Inc. has secured a $3 million grant from the NIH to propel its Alzheimer’s vaccine, Duvax, into human trials. This innovative vaccine aims to combat cognitive decline by targeting amyloid beta and tau proteins. Additionally, a promising new vaccine focusing on phosphorylated tau has demonstrated success in animal studies, reducing tau accumulation and enhancing memory, paving the way for affordable Alzheimer’s treatments.